As of Aug 31
| -0.99 / -2.70%|
The 10 analysts offering 12-month price forecasts for Sarepta Therapeutics Inc have a median target of 44.00, with a high estimate of 62.00 and a low estimate of 31.00. The median estimate represents a +23.25% increase from the last price of 35.70.
The current consensus among 12 polled investment analysts is to Buy stock in Sarepta Therapeutics Inc. This rating has held steady since August, when it was upgraded from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.